Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

European Council Conclusion on personalised medicine for patients (2015/C 421/03). Accessed on 21 October 2019. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XG1217(01)&from=EN. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014;33(7):1246–53. Personalized Medicine Coalition. Personalized Medicine at FDA: The Scope and Significance of Progress in 2020. Report 2020. http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_A_Progress_and_Outlook_Report.pdf. Nimmesgern E, Norstedt I, Draghia-Akli R. Enabling personalized medicine in Europe by the European Commission’s funding activities. Per Med. 2017;14(4):355–65. International Consortium for Personalised Medicine (ICPerMed). Accessed on 12 October 2021. https://www.icpermed.eu/. Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, et al. Integrating genomics into healthcare: a global responsibility. Am J Hum Genet. 2019;104(1):13–20. Khoury MJ, Bowen MS, Burke W, Coates RJ, Dowling NF, Evans JP, et al. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med. 2011;40(4):486–93. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694–701. Roberts MC, Kennedy AE, Chambers DA, Khoury MJ. The current state of implementation science in genomic medicine: opportunities for improvement. Genet Med. 2017;19(8):858–63. Touchot N, Flume M. Early insights from commercialization of gene therapies in Europe. Genes. 2017;8(2):78. Phillips KA. Evolving payer coverage policies on genomic sequencing tests: beginning of the end or end of the beginning? JAMA. 2019;319(23):2379–80. National Institute for Health and Care Excellence. Accessed on 25 March 2021. https://www.nice.org.uk/guidance/ta630. Jorgensen J, Kefalas P. Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test. J Mark Access Health Policy. 2017;5(1):1355203. Govaerts L, Simoens S, Van Dyck W, Huys I. Shedding light on reimbursement policies of companion diagnostics in European Countries. Value in Health. 2020;23(5):606–15. Koleva-Kolarova R, Tsiachristas A, Buchanan J, Wordsworth S. Systematic review of financing and reimbursement models for personalised medicine. PROSPERO 2019 CRD42019146764. Accessed on 21 October 2019. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019146764. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. Personalized Medicine Coalition. Accessed on 12 October 2021. http://www.personalizedmedicinecoalition.org/. European Alliance for Personalised Medicine. Accessed on 12 October 2021. https://www.euapm.eu/. International Society of Pharmacoeconomics and Outcomes Research Special Interest Groups: Precision Medicine and Advanced Therapies. Accessed on 12 October 2021. https://www.ispor.org/member-groups/special-interest-groups/personalized-precision-medicine. International Society of Pharmacoeconomics and Outcomes Research Special Interest Groups: Medical Devices and Diagnostics. Accessed on 12 October 2021. Available from: https://www.ispor.org/member-groups/special-interest-groups/medical-devices-and-diagnostics. International Society of Pharmacoeconomics and Outcomes Research Special Interest Groups: Rare Diseases. Accessed on 12 October 2021. https://www.ispor.org/member-groups/special-interest-groups/rare-disease. International Federation of Health Plans. Accessed on 12 October 2021. http://www.ifhp.com/. European Network for Health Technology Assessment. Accessed on 12 October 2021. https://eunethta.eu/. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuiset T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–3. Oordt-Speets AM, Bolijn R, van Hoorn RC, Bhavsar A, Kyaw MH. Global etiology of bacterial meningitis: a systematic review and meta-analysis. PLoS ONE. 2018;13(6):e0198772. Sayers A. Tips and tricks in performing a systematic review. Br J Gen Pract. 2007;57(542):759. Hanna E, Toumi M, Dussart C, Borissov B, Dabbous O, Badora K, et al. Funding breakthrough therapies: a systematic review and recommendation. Health Policy. 2018;122(3):217–29. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179–90. Mechanic RE, Altman SH. Payment reform options: episode payment is a good place to start. Health Aff (Millwood). 2009;28(2):w262–71. Polychronakos C. Public funding for genomics: where does Canada stand? J Med Genet. 2012;49(8):481–2. Power A, Berger AC, Ginsburg GS. Genomics-enabled drug repositioning and repurposing: insights from an IOM roundtable activity. JAMA. 2014;311(20):2063–4. Prasanna PG, Narayanan D, Hallett K, Bernhard EJ, Ahmed MM, Evans G, et al. Radioprotectors and radiomitigators for improving radiation therapy: the small business innovation research (SBIR) gateway for accelerating clinical translation. Radiat Res. 2015;184(3):235–48. Radda GK, Viney I. From gene function to improved health: genome research in the United Kingdom. J Mol Med. 2004;82(2):74–90. Ratner M. ARRA boosts cancer programs but impact on personalized medicine unclear. Nat biotechnol. 2009;27(12):1062. Rosenmayr-Templeton L. An industry update: What’s new in the field of therapeutic delivery? Ther Deliv. 2017;8(12):1027–33. Sankar PL, Parker LS. The Precision Medicine Initiative’s All of Us Research Program: an agenda for research on its ethical, legal, and social issues. Genet Med. 2017;19(7):743–50. Shah SH, Arnett D, Houser SR, Ginsburg GS, MacRae C, Mital S, et al. Opportunities for the cardiovascular community in the precision medicine initiative. Circulation. 2016;133(2):226–31. Shanks E, Ketteler R, Ebner D. Academic drug discovery within the United Kingdom: Aa reassessment. Nat Rev Drug Discovery. 2015;14(7):510. Siebert U, Jahn B, Rochau U, Schnell-Inderst P, Kisser A, Hunger T, et al. Oncotyrol - Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. Zeitschrift Fur Evidenz Fortbildung Und Qualitaet Im Gesundheitswesen. 2015;109(4–5):330–40. Sinclair A, Islam S, Jones S. Gene therapy: an overview of approved and pipeline technologies. Can Agency Drugs Technol Health. 2016;171:1–23. Sorlie PD, Sholinsky PD, Lauer MS. Reinvestment in government-funded research: a great way to share. Circulation. 2015;131(1):17–8. Steven BG. Pharmaceutical Dealmaking Broadens its Partnering Base: Collaborative R&D models coincide with new ways to fund translational research. BioPharm Int. 2012;25(7):16–7. Stulberg E, Fravel D, Proctor LM, Murray DM, LoTempio J, Chrisey L, et al. An assessment of US microbiome research. Nat. 2016;1:15015. Syme R, Carleton B, Leyens L, Richer E. Integrating personalized medicine in the Canadian Environment: efforts facilitating oncology clinical research. Public Health Genomics. 2015;18(6):372–80. Vis DJ, Lewin J, Liao RG, Mao M, Andre F, Ward RL, et al. Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape. Ann Oncol. 2017;28(5):1145–51. Kudrin A. Business models and opportunities for cancer vaccine developers. Hum Vaccin Immunother. 2012;8(10):1431–8. Iizuka T, Uchida G. Promoting innovation in small markets: evidence from the market for rare and intractable diseases. J Health Econ. 2017;54:56–65. Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics. 2009;12(3):134–41. Hirsch BR, Schulman KA. The economics of new drugs: can we afford to make progress in a common disease? Am Soc Clin Oncol Educ Book. 2013. Zhavoronkov A, Cantor CR. From personalized medicine to personalized science: uniting science and medicine for patient-driven, goal-oriented research. Rejuvenation Res. 2013;16(5):414–8. Basu A, Subedi P, Kamal-Bahl S. Financing a cure for diabetes in a multipayer environment. Value Health. 2016;19(6):861–8. Demotes-Mainard J, Canet E, Segard L. Public-private partnership models in France and in Europe. Therapie. 2006;61(4):325–34 (13-23). Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Pharm. 2015;8:99–110. Chignard M, Ramphal R. Basic research funding by philanthropic organizations: a case in point. Am J Respir Crit Care Med. 2013;188(11):1376–8. Glick JL. Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry. J Commer Biotechnol. 2009;15(4):324–34. Innovahealth conference. Building an Open Innovation ecosystem in Europe for healthcare. Report 2012. https://www.euapm.eu/pdf/EAPM_iNNOVAHEALTH_Final_Report.pdf. Sanne JL. Horizon 2020 SME-Instrument topic: clinical research for the validation of biomarkers and/or diagnostic medical devices. Pers Med. 2018;15(4):303–9. Hong JLA, Brechbiel M, Buchsbaum J, Canaria CA, Coleman CN, Escorcia FE, et al. National Cancer Institute support for targeted alpha-emitter therapy. Eur J Nucl Med Mol Imaging. 2021:9. Rosenmayr-Templeton L. Industry update for May 2019. Ther Deliv. 2019;10(9):555–61. Simpson I. Therapeutic delivery: industry update covering January 2019. Ther Deliv. 2019;10(5):273–80. Vuga LJ, Aggarwal NR, Reineck LA, Kalantari R, Banerjee K, Kiley J. Rare Lung Disease Research: National Heart, Lung, and Blood Institute’s Commitment to Partnership and Progress. Chest. 2019;156(3):438–44. Romagnuolo I, Mariut C, Mazzoni A, Santis G, Moltzen E, Ballensiefen W, et al. Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives. Pers Med. 2021;18(5):455–70. Singer DRJ, Marsh A. Challenges and solutions for personalizing medicines. Health Policy Technol. 2012;1(1):50–7. Rasi G. Promoting innovation at National level. Pharma Policy Law. 2010;12(1–2):125–7. Ward JC. Oncology reimbursement in the era of personalized medicine and big data. J Oncol Pract. 2014;10(2):83–6. Jorgensen J, Kefalas P. Reimbursement of licensed cell and gene therapies across the major European healthcare markets. J Mark Access Health Policy. 2015;3:103420. Ramsey SD, Sullivan SD. A new model for reimbursing genome-based cancer care. Oncologist. 2014;19(1):1–4. Trosman JR, Weldon CB, Gradishar WJ, Benson A, Cristofanilli M, Kurian AW, et al. From the past to the present: insurer coverage frameworks for next-generation tumor sequencing. Value Health. 2018;21(9):1062–8. van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019;30(5):663-5. Faulkner A, Mahalatchimy A. The politics of valuation and payment for regenerative medicine products in the UK. New Genet Soc. 2018;37(3):227–47. Duhig AM, Saha S, Smith S, Kaufman S, Hughes J. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. J Manag Care Spec Pharm. 2018;24(5):410–5. de Souza JA, Ratain MJ, Fendrick AM. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. J Natl Compr Canc Netw. 2012;10(1):18–23. Danzon PM. Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures. Value in Health. 2018;21(3):252–7. Akhmetov I, Bubnov RV. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine? Epma J. 2017;8(1):5–15. MIT NEWDIGS White Paper 2019F201-v023 Precision Financing Solutions for Durable / Potentially Curative Therapies. White paper 2019. https://newdigs.mit.edu/sites/default/files/MIT%20FoCUS%20Precision%20Financing%202019F201v023.pdf. Personalized Medicine Coalition. Paying for personalized medicine: how alternative payment models could help or hinder the field. White paper 2015. https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/paying_for_personalized_medicine.pdf. Carr DR, Bradshaw SE. Gene therapies: the challenge of super-high-cost treatments and how to pay for them. Regen Med. 2016;11(4):381–93. Editorial. Gene therapy's next installment. Nat biotechnol. 2019;37(7):697. Picecchi D, Bertram K, Brucher D, Bauer M. Towards novel reimbursement models for expensive advanced therapy medicinal products (ATMPs). Swiss Med Wkly. 2020;150:w20355. Horgan D, Metspalu A, Ouillade MC, Athanasiou D, Pasi J, Adjali O, et al. Propelling healthcare with advanced therapy medicinal products: a policy discussion. Biomed. 2020;5(3):130–52. Pearson SD, Dreitlein WB, Henshall C, Towse A. Indication-specific pricing of pharmaceuticals in the US healthcare system. J Comp Eff Res. 2017;6(5):397–404. Dinan MA, Lyman GH, Schilsky RL, Hayes DF. Proposal for value-based, tiered reimbursement for tumor biomarker tests to promote innovation and evidence generation. JCO Precis Oncol. 2019;3:1–10. Senior M. Rollout of high-priced cell and gene therapies forces payer rethink. Nat biotechnol. 2018;36(4):291–2. Pothier K, Gustavsen G. Combating complexity: partnerships in personalized medicine. Pers Med. 2013;10(4):387–96. Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018;26(12):2717–26. Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell. 2016;19(3):293–7. Yu TTL, Gupta P, Ronfard V, Vertes AA, Bayon Y. Recent progress in European advanced therapy medicinal products and beyond. Front. 2018;6:130. Pauly MV. Cost Sharing in Insurance Coverage for Precision Medicine. National Bureau of Economic Research, Inc, NBER Working Papers: 24095; 2017. Petelin L, James PA, Trainer AH. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia. Int Med J. 2018;48(10):1269–72. Plothner M, Klora M, Rudolph D, Graf von der Schulenburg JM. Health-Related Genetic Direct-to-Consumer Tests in the German Setting: The Available Offer and the Potential Implications for a Solidarily Financed Health-Care System. Public Health Genomics. 2017;20(4):203-17. Plun-Favreau J, Immonen-Charalambous K, Steuten L, Strootker A, Rouzier R, Horgan D, et al. Enabling equal access to molecular diagnostics: what are the implications for policy and health technology assessment? Public Health Genomics. 2016;19(3):144–52. Powell A, Chandrasekharan S, Cook-Deegan R. Spinocerebellar ataxia: patient and health professional perspectives on whether and how patents affect access to clinical genetic testing. Genet Med. 2010;12(4 Suppl):S83–110. Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance “personalized medicine” in cancer treatment. Health Aff (Millwood). 2011;30(12):2259–68. Roberts MC, Dusetzina SB. Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers. J Oncol Pract. 2015;11(4):273–7. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477–93. Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hafemeister L, et al. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer. 2012;3(1):16–22. Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer. 2018;18(1):269. Ryska A, Buiga R, Fakirova A, Kern I, Olszewski W, Plank L, et al. Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group. Oncologist. 2018;23(12):E152–8. Shah A, Harris H, Brown T, Graf MD, Sparks L, Mullins T, et al. Analysis of insurance preauthorization requests for BRCA1 and BRCA2 genetic testing: experience of the Humana Genetic Guidance Program. Pers Med. 2011;8(5):563–9. Shah P, Nathanson K, Holmes AM, Hadjiliadis D. Diagnosis of adult hereditary pulmonary disease and the role of genetic testing. Chest. 2010;137(4):976–82. Steffen JA. Diffusion of molecular diagnostic lung cancer tests: a survey of german oncologists. J. 2014;4(1):102-14. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80. Sutherland S, Farrell RM, Lockwood C. Genetic screening and testing in an episode-based payment model: preserving patient autonomy. Obstet Gynecol. 2014;124(5):987–91. Towse A, Garrison L. Value assessment in precision cancer medicine. J Cancer Policy. 2017;11:48–53. Towse A, Garrison LP Jr. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value in Health. 2013;16(6 Suppl):S39-43. Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J. 2013;3(4):288-305. Walcoff SD, Pfeifer JD. Modernizing US regulatory and reimbursement policy to support continued innovation in genomic pathology. Pers Med. 2012;9(3):295–308. Wu AC, Mazor KM, Ceccarelli R, Loomer S, Lu CY. The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies. J. 2018;8(4):01. Wurcel V, Perche O, Lesteven D, Williams DA, Schafer B, Hopley C, et al. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe. Public Health Genomics. 2016;19(3):137–43. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DGB, McCormack R, et al. Breaking a Vicious Cycle. Science Translational Medicine. 2013;5(196):196cm6-cm6. Hilal T, Betcher JA, Leis JF. Economic impact of oral therapies for chronic lymphocytic leukemia-the burden of novelty. Curr Hematol Malig Rep. 2018;13(4):237–43. Hsiao SJ, Mansukhani MM, Carter MC, Sireci AN. The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests: Transition from Stacking Codes to the Current Molecular Code Set Including Genomic Sequencing Procedures. J Mol Diagn. 2018;20(2):177–83. Klein RD. Reimbursement in molecular pathology: bringing genomic medicine to patients. Clin Chem. 2015;61(1):136–8. Kudrin A. Reimbursement challenges with cancer immunotherapeutics. Hum Vaccin Immunother. 2012;8(9):1326–34. Leopold C, Vogler S, Habl C, Mantel-Teeuwisse AK, Espin J. Personalised medicine as a challenge for public pricing and reimbursement authorities—a survey among 27 European countries on the example of trastuzumab. Health Policy. 2013;113(3):313–22. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy. 2010;94(2):91–100. Merlin T, Farah C, Schubert C, Mitchell A, Hiller JE, Ryan P. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. Med Decis Making. 2013;33(3):333–42. Mihajlovic J, Dolk C, Tolley K, Simoens S, Postma MJ. Reimbursement of targeted cancer therapies within 3 different European health care systems. Clin Ther. 2015;37(2):474–80. Cohen JP, Felix AE. Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. J. 2014;4(2):163-75. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. 2013;13(4):378–88. Garfield S. Advancing Access to Personalized Medicine: A Comparative Assessment of European Reimbursement Systems. Personalized Medicine Coalition. Bridgehead International. 2011. http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_bridgehead_issue_brief_european_reimbursement.pdf. Institute of Medicine (US). Genome-Based Diagnostics: Clarifying Pathways to Clinical Use: Workshop Summary. Washington (DC): National Academies Press (US); 2012. PMID: 22934323. Wilsdon T, Barron A, Edwards G, Lawlor R, Charles River Associates. The benefits of personalised medicine to patients, society and healthcare systems. Final Report 2018. https://www.efpia.eu/media/362040/cra-ebe-efpia-benefits-of-pm-final-report-6-july-2018.pdf. Sireci AN, Aggarwal VS, Turk AT, Gindin T, Mansukhani MM, Hsiao SJ. Clinical genomic profiling of a diverse array of oncology specimens at a large academic cancer center: identification of targetable variants and experience with reimbursement. J Mol Diagn. 2017;19(2):277–87. Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, et al. Market access challenges in the EU for high medical value diagnostic tests. Pers Med. 2011;8(2):137–48. Campbell JD, Whittington MD. Paying for CAR-T therapy amidst limited health system resources. J Clin Oncol. 2019;37(24):2095–7. Jacobson C, Emmert A, Rosenthal MB. CAR T-cell therapy: a microcosm for the challenges ahead in medicare. JAMA. 2019;322(10):923–4. Leech AA, Dusetzina SB. Cost-effective but unaffordable: the CAR-T conundrum. J Natl Cancer Inst. 2019;111(7):644–5. Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transp. 2020;55(9):1706–15. Jorgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536. Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40:1–8. Jorgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16(4):405–22. Ronco V, Dilecce M, Lanati E, Canonico PL, Jommi C. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? Journal of Pharmaceutical Policy and Practice. 2021;14(30). Sharpe M, Barry J, Kefalas P. Clinical adoption of advanced therapies: challenges and opportunities. J Pharm Sci. 2021;110(5):1877–84. Wilking N, Bucsics A, Kandolf Sekulovic L, Kobelt G, Laslop A, Makaroff L, et al. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): Summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. ESMO Open. 2019;4(6):e000550. Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, et al. Access to innovative medicines for metastatic melanoma worldwide: melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018;104:201–9. Hsiao SJ, Sireci AN, Pendrick D, Freeman C, Fernandes H, Schwartz GK, et al. Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology. JCO Precis Oncol. 2020;4:1038–48. Klein RD. Current policy challenges in genomic medicine. Clin Chem. 2020;66(1):61–7. Rogers SL, Keeling NJ, Giri J, Gonzaludo N, Jones JS, Glogowski E, et al. PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing. Pharmacogenomics. 2020;21(11):785–96. Thunnissen E, Weynand B, Udovicic-Gagula D, Brcic L, Szolkowska M, Hofman P, et al. Lung cancer biomarker testing: perspective from Europe. Transl. 2020;9(3):887–97. Mullangi S, Schleicher SM, Parikh RB. The oncology care model at 5 years-value-based payment in the Precision Medicine Era. JAMA Oncol. 2021;7(9):1283–4. Pruneri G, Tondini CA. The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model. Tumori. 2021;107(2):166–70. Andersson E, Svensson J, Persson U, Lindgren P. Risk sharing in managed entry agreements—a review of the Swedish experience. Health Policy. 2020;124(4):404–10. Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171. Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the European perspective. Value Health. 2020;23(4):425–33. Whittington MD, McQueen RB, Campbell JD. Valuing chimeric antigen receptor T-cell therapy: current evidence, uncertainties, and payment implications. J Clin Oncol. 2020;38(4):359–66. Starner CI, Gleason PP. Spinal muscular atrophy therapies: ICER grounds the price to value conversation in facts. J Manag Care Spec Pharm. 2019;25(12):1306-8. Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group. Value Health. 2012;15(8):1162–71. Cohen JP. Personalized medicine: are payers the weak link? Pers Med. 2011;8(3):293–6. Abou-El-Enein M, Bauer G, Medcalf N, Volk HD, Reinke P. Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016;18(8):1056–61. Fugel HJ, Nuijten M, Postma M. Stratified medicine and reimbursement issues. Front Pharmacol. 2012;3:181. Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793–9. Blair ED, Stratton EK, Kaufmann M. Aligning the economic value of companion diagnostics and stratified medicines. J. 2012;2(4):257-66. Garrison LP, Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. J. 2017;7(3):04. Garrison LP Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev. 2008;40(2):377–401. Crawford JM, Aspinall MG. The business value and cost-effectiveness of genomic medicine. Pers Med. 2012;9(3):265–86. Brooks GA, Bosserman LD, Mambetsariev I, Salgia R. Value-based medicine and integration of tumor biology. Am. 2017;37:833–40. Lyerly HK, Ren J, Canetta R, Kim GH, Nagai S, Yamaguchi T, et al. Global development of anticancer therapies for rare cancers, pediatric cancers, and molecular subtypes of common cancers. J Glob Oncol. 2018;4:1–11. Lennerz JK, McLaughlin HM, Baron JM, Rasmussen D, Shin MS, Berners-Lee N, et al. Health care infrastructure for financially sustainable clinical genomics. J Mol Diagn. 2016;18(5):697–706. Personalized Medicine Coalition. The future of coverage and payment for personalized medicine diagnostics. White paper 2014. http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_the_future_coverage_payment_personalized_medicine_diagnostics.pdf. Engstrom PF, Bloom MG, Demetri GD, et al. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw. 2011;9(suppl 6):S1–16. Knowles L, Luth W, Bubela T. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. J Law Biosci. 2017;4(3):453–506. Merlin T. The use of the “linked evidence approach” to guide policy on the reimbursement of personalized medicines. Pers Med. 2014;11(4):435–48. Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff (Millwood). 2015;34(2):302–10. Greaves RF, Bernardini S, Ferrari M, Fortina P, Gouget B, Gruson D, et al. Key questions about the future of laboratory medicine in the next decade of the 21st century: a report from the IFCC-Emerging Technologies Division. Clin Chim Acta. 2019;495:570–89. Koh CYC, Seager TP. Value-based pharmaceutical pricing from the patient perspective could incentivize innovation. Pharm Med. 2017;31(3):149–53. Vozikis A, Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V, et al. Test pricing and reimbursement in genomic medicine: towards a general strategy. Public Health Genomics. 2016;19(6):352–63. Halfmann SSG, Evangelatos N, Schroder-Back P, Brand A. European healthcare systems readiness to shift from “one-size fits all” to personalized medicine. Pers Med. 2017;14(1):63–74. Antonanzas F, Rodriguez-Ibeas R, Juarez-Castello CA. Personalized medicine and pay for performance: should pharmaceutical firms be fully penalized when treatment fails? Pharmacoeconomics. 2018;36(7):733–43. Emery JCH, Zwicker JD. Innovation, productivity, and pricing: capturing value from precision medicine technology in Canada. Healthc Manage Forum. 2017;30(4):197–9. Deverka PA, Dreyfus JC. Clinical integration of next generation sequencing: coverage and reimbursement challenges. J Law Med Ethics. 2014;42(Suppl 1):22–41. Deverka PA. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics. 2009;12(3):149–57. Danko D, Blay JY, Garrison LP. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. Health Policy. 2019;123(12):1230–6. Garrison LP Jr, Towse A. A strategy to support efficient development and use of innovations in personalized medicine and precision medicine. J Manag Care Spec Pharm. 2019;25(10):1082–7. Faulkner E, Holtorf AP, Walton S, Liu CY, Lin H, Biltaj E, et al. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? a report of the Personalized Precision Medicine Special Interest Group. Value Health. 2020;23(5):529–39. Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. BMJ Glob Health. 2021;6(2):e004415. Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies. Front Pharmacol. 2020;11:594446. Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, et al. Bringing greater accuracy to Europe’s Healthcare Systems: the unexploited potential of biomarker testing in oncology. Biomed. 2020;5(3):182–223. Personalized Medicine Coalition. Understanding genomic testing utilization and coverage in the US. Report 2020. https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PMC_Understanding_Genomic_Testing_Utilization_and_Coverage_in_the_US2.pdf. Personalized Medicine Coalition. Personalized Medicine At FDA: A Progress & Outlook Report. Report 2019. https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_A_Progress_and_Outlook_Report.pdf. Frueh FW. Regulation, reimbursement, and the long road of implementation of personalized medicine-a perspective from the United States. Value in Health. 2013;16(6):S27–31. Cherla A, Howard N, Mossialos E. The “Netflix plus model”: can subscription financing improve access to medicines in low- and middle-income countries? Health Econ Policy Law. 2021;16(2):113–23. Moon S, Erickson E. Universal medicine access through lump-sum remuneration—Australia’s Approach to Hepatitis C. N Engl J Med. 2019;380(7):607–10. Financial Times. Table: the top social global impact bonds. Accessed on 4 August 2020. https://www.ft.com/content/99b49376-eea6-11e8-89c8-d36339d835c0. 2018. Social Finance. Social Impact Bonds. Accessed on 4 August 2020. https://www.socialfinance.org.uk/what-we-do/social-impact-bonds. 2018. Berndt C, Wirth M. Market, metrics, morals: the social impact bond as an emerging social policy instrument. Geoforum. 2018;90:27–35. Government UK. Social Impact Bonds. Guidance. Accessed on 4 August 2020. https://www.gov.uk/guidance/social-impact-bonds. 2012. Neumann PJ. Yes, improve the US value frameworks, but recognize they are already in prime time. Value Health. 2019;22(9):975–6. Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-A health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–9. Dakin H, Gray A. Decision making for healthcare resource allocation: joint v. separate decisions on interacting interventions. Med Decis Making. 2018;38(4):476–86. van de Wetering EJ, van Exel J, Brouwer WB. The challenge of conditional reimbursement: stopping reimbursement can be more difficult than not starting in the first place! Value Health. 2017;20(1):118–25. Drummond M, Towse A. Is rate of return pricing a useful approach when value-based pricing is not appropriate? Eur J Health Econ. 2019;20(7):945–8. Flodgren G, Eccles MP, Shepperd S, Scott A, Parmelli E, Beyer FR. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. Cochrane Database Syst Rev. 2011;2011(7):Cd009255. Sarnak DO, Squires D, Kuzmak G, Bishop S, Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? The Commonwealth Fund, October 2017. Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot. 2016;69(2):73–88.